ARTICLE | Emerging Company Profile
Abata: engineering targeted Treg cell therapies with TCRs
Emerging Company Profile: Third Rock launches Abata with $95M series A to develop targeted Treg cell therapies for autoimmune disorders
June 23, 2021 11:20 AM UTC
BCIQ Company Profiles